Patents Assigned to GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
  • Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
    Patent number: 11649217
    Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: May 16, 2023
    Assignee: GlaxoSmithKline Intellectual Property (NO.2) Limited
    Inventors: Minhua Chen, Yanfeng Zhang, Jinqiu Wang, Xiaoyu Zhang
  • 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 11478478
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: October 25, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Biopharmaceutical compositions
    Patent number: 11459384
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: October 4, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • COMPOUNDS USEFUL IN HIV THERAPY
    Publication number: 20220298160
    Abstract: The invention relates to compounds of Formulae (I)-(II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 22, 2022
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, VIIV HEALTHCARE COMPANY
    Inventors: Martha Alicia DE LA ROSA, John MILLER, Lita S. SUWANDI, David TEMELKOFF, Emile Johann VELTHUISEN
  • 4'-ETHYNYL-2'-DEOXYADENOSINE DERIVATIVES AND THEIR USE IN HIV THERAPY
    Publication number: 20220259252
    Abstract: The invention relates to compounds of Formulae (I) and (II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
    Type: Application
    Filed: July 30, 2020
    Publication date: August 18, 2022
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, VIIV HEALTHCARE COMPANY
    Inventors: John MILLER, Vicente SAMANO, David TEMELKOFF, Emile Johann VELTHUISEN
  • 2,3-dihydrobenzohurans as bromodomain inhibitors
    Patent number: 11319307
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: May 3, 2022
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Simon Christopher Cranko Lucas, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Compounds Useful in HIV Therapy
    Publication number: 20220117993
    Abstract: The invention relates to compounds of the Formula: salts thereof, pharmaceutical compositions thereof, combinations thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: August 8, 2019
    Publication date: April 21, 2022
    Applicants: GlaxoSmithKline Intellectual Property (No. 2) Limited, VIIV Healthcare Company
    Inventors: John Franklin MILLER, David TEMELKOFF, Emile Johann VELTHUISEN, Martha Alicia DE LA ROSA, Lita SUWANDI, B. Narasimhulu NAIDU
  • Biopharmaceutical compositions
    Patent number: 11299541
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: April 12, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Chemical compounds
    Patent number: 11299457
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: April 12, 2022
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • Biopharmaceutical compositions
    Patent number: 11286298
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: March 29, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Biopharmaceutical compositions
    Patent number: 11274148
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: March 15, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Benzofuran derivatives and their use as bromodomain inhibitors
    Patent number: 11273146
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: March 15, 2022
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Simon Christopher Cranko Lucas, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • TRPV4 antagonists
    Patent number: 11260049
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 1, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Peng Li, Jay M. Matthews, John Jeffrey McAtee, Joseph E. Pero, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm
  • TRPV4 antagonists
    Patent number: 11229623
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: January 25, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas
  • 4-substituted benzoxaborole compounds and uses thereof
    Patent number: 11214582
    Abstract: Substituted benzoxaboroles whose structure comprises Formula (III), wherein R3 is selected from —CH3, —CII2CII3, —CII2?CII2, —CII2CII2CII3, —CH(CH3)2, —CH2CH2?CH2, and cyclopropyl, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, and —CH(CH3)2; compositions containing such compounds, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: January 4, 2022
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, ANACOR PHARMACEUTICALS, INC.
    Inventors: Carlos Alemparte-Gallardo, Michael Richard Kevin (Dickon) Alley, David Barros-Aguirre, Ilaria Giordano, Vincent Hernandez, Xianfeng Li, Jacob J. Plattner
  • Synthetic methods
    Patent number: 11186558
    Abstract: Methods for the preparation of the following compound are disclosed. The compound can be incorporated into pharmaceutical formulations, including tablets and such tablets can be used for treating cholestatic liver diseases.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: November 30, 2021
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Gregg Barcan, Jiasheng Guo, Christopher W. Morgan, Gheorghe D. Roiban, Peter W. Sutton
  • Compounds Useful in HIV Therapy
    Publication number: 20210323993
    Abstract: The invention relates to compounds of Formulae (I), (Ia), (II) and (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
    Type: Application
    Filed: August 28, 2019
    Publication date: October 21, 2021
    Applicants: GlaxosmithKline Intellectual Property (No. 2) Limited, ViiV Healthcare Company
    Inventors: John MILLER, David TEMELKOFF, Emile Johann VELTHUISEN, Martha Alicia DE LA ROSA, Lisa SUWANDI
  • Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
    Patent number: 11117871
    Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 14, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Minhua Chen, Yanfeng Zhang, Jinqiu Wang, Xiaoyu Zhang
  • Crystalline forms
    Patent number: 11001556
    Abstract: This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: May 11, 2021
    Assignee: Glaxosmithkline Intellectual Property (No.2) Limited
    Inventors: Istvan Kaldor, Dalin Tang
  • Pyrazole derivatives as bromodomain inhibitors
    Patent number: 10966961
    Abstract: The present invention is directed to pyrazole derivatives, pharmaceutical compositions comprising the compounds and the use of the compounds or the compositions in the treatment of various diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: April 6, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Gemma Michele Liwicki, Simon Christopher Cranko Lucas, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson